Briquilimab Reference: HY-P99488 Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID).
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 500ug Reference: AT7001-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Enfortumab Reference: HY-P99016 Enfortumab is a monoclonal antibody targeting Nectin-4. Enfortumab can used for researching urothelial cancer.
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 1mg Reference: AT7001-1000 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Izuralimab Reference: HY-P99679 Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1.
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 100ug mIgG1 Ab Reference: AT7001-mIgG1-100 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
Anatumomab mafenatox Reference: HY-P99436 Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness.
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 500ug mIgG1 Ab Reference: AT7001-mIgG1-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com